Skip to main content
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.870
+0.030 (1.63%)
At close: Dec 20, 2024, 4:00 PM
1.900
+0.030 (1.60%)
After-hours: Dec 20, 2024, 5:42 PM EST

Allogene Therapeutics Revenue

Allogene Therapeutics had revenue of $43.00K in the twelve months ending September 30, 2024, up 26.47% year-over-year. In the year 2023, Allogene Therapeutics had annual revenue of $95.00K, down -39.10%.

Revenue (ttm)
$43.00K
Revenue Growth
+26.47%
P/S Ratio
n/a
Revenue / Employee
$185
Employees
233
Market Cap
392.09M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202395.00K-61.00K-39.10%
Dec 31, 2022156.00K-113.93M-99.86%
Dec 31, 2021114.09M--
Dec 31, 2020---
Dec 31, 2019---
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Enhabit 1.04B
Akebia Therapeutics 169.88M
Quanterix 129.33M
Y-mAbs Therapeutics 84.55M
Alpha Teknova 36.35M
Nano-X Imaging 10.68M
Taysha Gene Therapies 9.92M
Revenue Rankings

ALLO News

More News